Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648347 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
A Phase 3 study of Anemia and Non-Dialysis-Dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,751
- Enrollment target
- 20
- Study locations
NCT02648347 is a Phase 3 study of Anemia and Non-Dialysis-Dependent Chronic Kidney Disease that has completed, run by Akebia Therapeutics. The registered enrollment target is 1,751 participants, above the 403-participant average among 72 other Anemia trials with a reported enrollment target (334% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT02648347, a Phase 3 study of Anemia and Non-Dialysis-Dependent Chronic Kidney Disease, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,751 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in participants with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
Conditions Studied
Interventions
- DRUG Vadadustat
- DRUG Darbepoetin alfa
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Bakersfield
- Research Site #1 - Chula Vista
- Research Site #2 - Chula Vista
- Research Site #1 - Fountain Valley
- Research Site #2 - Fountain Valley
- Research Site - Glendale
- Research Site - Granada Hills
- Research Site - La Mesa
- Research Site - Laguna Hills
- Research Site - Long Beach
- Research Site - Long Beach
- Research Site - Los Angeles
Arizona
- Research Site - Glendale
- Research Site - Mesa
- Research Site - Phoenix
- Research Site - Tucson
- Research Site - Tucson
Alabama
- Research Site - Huntsville
- Research Site - Tuscumbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,751 participants |
| Start Date | 2015-12 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02648347
The ClinicalTrials.gov registry entry for NCT02648347 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,751 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 403-participant average among 72 other Anemia trials with a reported enrollment target (334% higher). The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Vadadustat is the first listed.
NCT02648347 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02648347 about?
NCT02648347 is a clinical study titled "Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease". A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in participants with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
What is the current status of trial NCT02648347?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,751 participants. The study started on 2015-12. Estimated completion is 2020-07-31.
What conditions does trial NCT02648347 study?
This clinical trial studies the following conditions: Anemia, Non-Dialysis-Dependent Chronic Kidney Disease.
What interventions are being tested in trial NCT02648347?
The interventions under investigation include: Vadadustat (DRUG), Darbepoetin alfa (DRUG).
Who is sponsoring clinical trial NCT02648347?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02648347 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.